Clinical trial · Interventional
Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma
A Prospective Randomized Trial Comparing Cytoreductive Surgery Followed by Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Multinodular Hepatocellular Carcinoma (MNHCC)
NCT00820157CI-TRIAL-00011751TACEcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the surgical outcomes of cytoreductive surgery followed by Transarterial Chemoembolization (TACE) with TACE alone in patients with MNHCC so as to establish a treatment standard for MNHCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytoreductive Surgery | Procedure | — | UNRESOLVED |
| TACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Cytoreductive Surgery
- description
- Cytoreductive Surgery followed by TACE
- interventionNames
- Procedure: Cytoreductive Surgery
- type
- EXPERIMENTAL
- label
- TACE
- description
- TACE alone
- interventionNames
- Procedure: TACE
Primary outcomes (1)
- measure
- the overall survival rate of each group
- timeFrame
- 3 years
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female patients \> 18 years and \<=70 years of age. * at least 2 radiologic imaging showing characteristic features of HCC or one radiologic imaging associated with AFP \>400 or cytologic/histologic evidence. * tumor number \>3 and \<=5,maximum diameter \>5cm and \<=15cm;without evidence of radiologically definable vascular invasion or extrahepatic metastasis. * Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. * No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. * Hb ≥90g/L,WBC ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³ * Patients who can understand this trial and have signed information consent Exclusion Criteria: * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer. * Patients with other diseases which may affect the treatment mentioned. * Patients with a medical history of other malignant tumors. * Subjects participating in other clinical trials. * Extrahepatic metastasis, portal vein or other major vascular involvement. * liver function:Child C. * no pathological evidence of HCC.
References
Publications (0)
Data not yet available
No reference posted for this study.